933799-84-9

Upstream product

• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 933799-72-5 methyl 3-{2-chloro-4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}benzoylamino}benzoate 
• 103-63-9 1-phenyl-2-bromoethane 
• 898253-47-9 4-(bromomethyl)-3-(2,6-dichlorophenyl)-5-isopropyl-isoxazole 
• 278597-32-3 3-(2,6-dichlorophenyl)-4-(3'-chloro-4'-formylphenoxy)-methyl-5-isopropyl-isoxazole 
• 933799-64-5 2-chloro-4-{[5-isopropyl-3-(2,6-dichlorophenyl)-isoxazol-4-yl]methoxy}benzoic acid 

Relevant academic research and scientific papers

Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is caused by hereditary mutations of bile salt export pump (BSEP), such as E297G BSEP, which is a folding-defective mutant that is unable to traffic beyond the endoplasmic reticulum (ER). 4-Phen

Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist

A series of substituted-isoxazole derivatives was prepared as candidate farnesoid X receptor (FXR) antagonists, based on our previously proposed ligand superfamily concept. Structure-activity relationship studies indicated that the shape and the structura